Details of the Drug

General Information of Drug (ID: DMOJZQ9)

Drug Name

Loperamide

Synonyms

Ioperamide; Loperacap; Loperamida; Loperamidum; Kaopectate II; Loperamide Monohydrochloride; Pepto Diarrhea Control; Apo-Loperamide; Diamide (TN); Diarr-Eze; Dimor (TN); Imodium (TN); Imodium A-D Caplets; Loperamida [INN-Spanish]; Loperamide (INN); Loperamide [INN:BAN]; Loperamidum [INN-Latin]; Lopex (TN); Maalox Anti-Diarrheal; Nu-Loperamide; PMS-Loperamide; Pepto (TN); R-18553; Rho-Loperamide

Indication

Disease Entry	ICD 11	Status	REF
Diarrhea	ME05.1	Approved	[1]

Therapeutic Class

Antidiarrheals

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

477

Topological Polar Surface Area (xlogp)

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [2]
Elimination: 0.5% of drug is excreted from urine in the unchanged form [2]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.4791 micromolar/kg/day [3]
Water Solubility: The ability of drug to dissolve in water is measured as 1.4 mg/mL [2]

Chemical Identifiers

Formula: C29H33ClN2O2
IUPAC Name: 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide
Canonical SMILES: CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4
InChI: InChI=1S/C29H33ClN2O2/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32-20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3
InChIKey: RDOIQAHITMMDAJ-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3955
ChEBI ID: CHEBI:6532
CAS Number: 53179-11-6
DrugBank ID: DB00836
TTD ID: D0CS2F
VARIDT ID: DR00171
INTEDE ID: DR0974
ACDINA ID: D00373

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Opioid receptor delta (OPRD1)	TT27RFC	OPRD_HUMAN	Binder	[4]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[5]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[6]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[7]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Substrate	[7]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[7]
Oxygen-insensitive NADPH nitroreductase A (nfsA)	DEDPI65	NFSA_ECOLI	Substrate	[8]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Diarrhea

ICD Disease Classification

ME05.1

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Opioid receptor delta (OPRD1)	DTT	OPRD1	5.52E-01	0.03	0.23
P-glycoprotein 1 (ABCB1)	DTP	P-GP	7.83E-01	4.69E-02	1.89E-01
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	3.17E-01	-6.95E-02	-2.88E-01
Cytochrome P450 2B6 (CYP2B6)	DME	CYP2B6	5.79E-01	-1.30E-02	-9.78E-02
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	5.64E-01	2.36E-02	1.75E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	6.06E-01	-2.42E-02	-1.64E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Loperamide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Ivosidenib.	Acute myeloid leukaemia [2A60]	[62]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Midostaurin.	Acute myeloid leukaemia [2A60]	[62]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Idarubicin.	Acute myeloid leukaemia [2A60]	[62]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Gilteritinib.	Acute myeloid leukaemia [2A60]	[62]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Oliceridine.	Acute pain [MG31]	[62]
Mepyramine	DMB4SFH	Moderate	Additive antimotility effects by the combination of Loperamide and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[63]
Phenyltoloxamine	DMKAEQW	Moderate	Additive antimotility effects by the combination of Loperamide and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[63]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Loperamide when combined with Rivastigmine.	Alzheimer disease [8A20]	[64]
Donepezil	DMIYG7Z	Moderate	Antagonize the effect of Loperamide when combined with Donepezil.	Alzheimer disease [8A20]	[64]
Metronidazole	DMTIVEN	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Metronidazole.	Amoebiasis [1A36]	[62]
Bepridil	DM0RKS4	Major	Decreased clearance of Loperamide due to the transporter inhibition by Bepridil.	Angina pectoris [BA40]	[65]
Bedaquiline	DM3906J	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[62]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Cilostazol.	Arterial occlusive disease [BD40]	[62]
Posaconazole	DMUL5EW	Major	Decreased clearance of Loperamide due to the transporter inhibition by Posaconazole.	Aspergillosis [1F20]	[62]
Terbutaline	DMD4381	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Terbutaline.	Asthma [CA23]	[62]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[62]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[62]
Clarithromycin	DM4M1SG	Major	Decreased metabolism of Loperamide caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[62]
Sparfloxacin	DMB4HCT	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[62]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[62]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[62]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[62]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Loperamide caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[62]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[62]
Telithromycin	DMZ4P3A	Major	Decreased metabolism of Loperamide caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[62]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Retigabine.	Behcet disease [4A62]	[62]
Erdafitinib	DMI782S	Moderate	Decreased clearance of Loperamide due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[66]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Eribulin.	Breast cancer [2C60-2C6Y]	[62]
Lapatinib	DM3BH1Y	Major	Decreased clearance of Loperamide due to the transporter inhibition by Lapatinib.	Breast cancer [2C60-2C6Y]	[65]
Tucatinib	DMBESUA	Moderate	Decreased clearance of Loperamide due to the transporter inhibition by Tucatinib.	Breast cancer [2C60-2C6Y]	[67]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[62]
Dihydrocodeine	DMB0FWL	Moderate	Additive CNS depression effects by the combination of Loperamide and Dihydrocodeine.	Chronic pain [MG30]	[68]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Halothane.	Corneal disease [9A76-9A78]	[62]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Sevoflurane.	Corneal disease [9A76-9A78]	[62]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Probucol.	Coronary atherosclerosis [BA80]	[62]
Clofazimine	DMEBOFW	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Clofazimine.	Crohn disease [DD70]	[62]
Pasireotide	DMHM7JS	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Pasireotide.	Cushing syndrome [5A70]	[62]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Osilodrostat.	Cushing syndrome [5A70]	[62]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Loperamide caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[69]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Loperamide and Ethanol.	Cystitis [GC00]	[70]
Sertraline	DM0FB1J	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Sertraline.	Depression [6A70-6A7Z]	[62]
Cyclobenzaprine	DM1YBRM	Moderate	Additive antimotility effects by the combination of Loperamide and Cyclobenzaprine.	Depression [6A70-6A7Z]	[63]
Nefazodone	DM4ZS8M	Major	Decreased metabolism of Loperamide caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[62]
Escitalopram	DMFK9HG	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Escitalopram.	Depression [6A70-6A7Z]	[62]
OPC-34712	DMHG57U	Moderate	Additive antimotility effects by the combination of Loperamide and OPC-34712.	Depression [6A70-6A7Z]	[63]
Clomipramine	DMINRKW	Moderate	Additive antimotility effects by the combination of Loperamide and Clomipramine.	Depression [6A70-6A7Z]	[63]
Doxepin	DMPI98T	Moderate	Additive antimotility effects by the combination of Loperamide and Doxepin.	Depression [6A70-6A7Z]	[63]
Maprotiline	DMPWB7T	Moderate	Additive antimotility effects by the combination of Loperamide and Maprotiline.	Depression [6A70-6A7Z]	[63]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Loperamide and Esketamine.	Depression [6A70-6A7Z]	[71]
Mepenzolate	DM8YU2F	Moderate	Additive antimotility effects by the combination of Loperamide and Mepenzolate.	Digestive system disease [DE2Z]	[63]
Oxybutynine	DMJPBAX	Moderate	Additive antimotility effects by the combination of Loperamide and Oxybutynine.	Discovery agent [N.A.]	[63]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[62]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Deutetrabenazine.	Dystonic disorder [8A02]	[62]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Ingrezza.	Dystonic disorder [8A02]	[62]
Solifenacin	DMG592Q	Moderate	Additive antimotility effects by the combination of Loperamide and Solifenacin.	Functional bladder disorder [GC50]	[63]
Tolterodine	DMSHPW8	Moderate	Additive antimotility effects by the combination of Loperamide and Tolterodine.	Functional bladder disorder [GC50]	[63]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Loperamide caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[62]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Loperamide caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[62]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[62]
Boceprevir	DMBSHMF	Major	Decreased clearance of Loperamide due to the transporter inhibition by Boceprevir.	Hepatitis virus infection [1E50-1E51]	[62]
Telaprevir	DMMRV29	Major	Decreased metabolism of Loperamide caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[62]
GS-5885	DMSL3DX	Moderate	Decreased clearance of Loperamide due to the transporter inhibition by GS-5885.	Hepatitis virus infection [1E50-1E51]	[72]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[62]
Saquinavir	DMG814N	Moderate	Altered absorption of Loperamide due to GI dynamics variation caused by Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[73]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[62]
Atazanavir	DMSYRBX	Major	Decreased clearance of Loperamide due to the transporter inhibition by Atazanavir.	Human immunodeficiency virus disease [1C60-1C62]	[62]
Gemfibrozil	DMD8Q3J	Major	Decreased metabolism of Loperamide caused by Gemfibrozil mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[62]
BMS-201038	DMQTAGO	Moderate	Decreased clearance of Loperamide due to the transporter inhibition by BMS-201038.	Hyper-lipoproteinaemia [5C80]	[74]
Conivaptan	DM1V329	Major	Decreased clearance of Loperamide due to the transporter inhibition by Conivaptan.	Hypo-osmolality/hyponatraemia [5C72]	[62]
Tolvaptan	DMIWFRL	Moderate	Decreased clearance of Loperamide due to the transporter inhibition by Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[71]
Belladonna	DM2RBWK	Moderate	Additive antimotility effects by the combination of Loperamide and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[63]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Loperamide when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[64]
Crizotinib	DM4F29C	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Crizotinib.	Lung cancer [2C25]	[62]
Ceritinib	DMB920Z	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Ceritinib.	Lung cancer [2C25]	[62]
Osimertinib	DMRJLAT	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Osimertinib.	Lung cancer [2C25]	[62]
Capmatinib	DMYCXKL	Moderate	Decreased clearance of Loperamide due to the transporter inhibition by Capmatinib.	Lung cancer [2C25]	[75]
Selpercatinib	DMZR15V	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Selpercatinib.	Lung cancer [2C25]	[62]
Lumefantrine	DM29GAD	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Lumefantrine.	Malaria [1F40-1F45]	[62]
Halofantrine	DMOMK1V	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Halofantrine.	Malaria [1F40-1F45]	[62]
Hydroxychloroquine	DMSIVND	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Hydroxychloroquine.	Malaria [1F40-1F45]	[62]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Primaquine.	Malaria [1F40-1F45]	[62]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[62]
Idelalisib	DM602WT	Major	Decreased metabolism of Loperamide caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[62]
Arsenic trioxide	DM61TA4	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[62]
Ibrutinib	DMHZCPO	Moderate	Decreased clearance of Loperamide due to the transporter inhibition by Ibrutinib.	Mature B-cell lymphoma [2A85]	[68]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and LGX818.	Melanoma [2C30]	[62]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Loperamide and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[76]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Loperamide due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[77]
Flibanserin	DM70DTN	Major	Decreased clearance of Loperamide due to the transporter inhibition by Flibanserin.	Mood disorder [6A60-6E23]	[65]
Panobinostat	DM58WKG	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Panobinostat.	Multiple myeloma [2A83]	[62]
Siponimod	DM2R86O	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Siponimod.	Multiple sclerosis [8A40]	[62]
Fingolimod	DM5JVAN	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Fingolimod.	Multiple sclerosis [8A40]	[62]
Ozanimod	DMT6AM2	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Ozanimod.	Multiple sclerosis [8A40]	[62]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Romidepsin.	Mycosis fungoides [2B01]	[62]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Dasatinib.	Myeloproliferative neoplasm [2A20]	[62]
Phenindamine	DMDTC7R	Moderate	Additive antimotility effects by the combination of Loperamide and Phenindamine.	Nasopharyngitis [CA00]	[63]
Dimenhydrinate	DM264B3	Moderate	Additive antimotility effects by the combination of Loperamide and Dimenhydrinate.	Nausea/vomiting [MD90]	[63]
Promethazine	DM6I5GR	Moderate	Additive antimotility effects by the combination of Loperamide and Promethazine.	Nausea/vomiting [MD90]	[63]
Rolapitant	DM8XP26	Moderate	Decreased clearance of Loperamide due to the transporter inhibition by Rolapitant.	Nausea/vomiting [MD90]	[78]
Cyclizine	DM9G7BS	Moderate	Additive antimotility effects by the combination of Loperamide and Cyclizine.	Nausea/vomiting [MD90]	[63]
Granisetron	DMIUW25	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Granisetron.	Nausea/vomiting [MD90]	[62]
Ondansetron	DMOTQ1I	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Ondansetron.	Nausea/vomiting [MD90]	[62]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Entrectinib.	Non-small cell lung cancer [2C25]	[62]
Levomethadyl Acetate	DM06HG5	Moderate	Additive antimotility effects by the combination of Loperamide and Levomethadyl Acetate.	Opioid use disorder [6C43]	[68]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Lofexidine.	Opioid use disorder [6C43]	[62]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Loperamide and Apraclonidine.	Optic nerve disorder [9C40]	[79]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Rucaparib.	Ovarian cancer [2C73]	[62]
Flavoxate	DMKV4NL	Moderate	Additive antimotility effects by the combination of Loperamide and Flavoxate.	Pain [MG30-MG3Z]	[63]
Nalbuphine	DMOSQGU	Moderate	Additive CNS depression effects by the combination of Loperamide and Nalbuphine.	Pain [MG30-MG3Z]	[68]
Buprenorphine	DMPRI8G	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Buprenorphine.	Pain [MG30-MG3Z]	[62]
Hydrocodone	DMQ2JO5	Moderate	Additive CNS depression effects by the combination of Loperamide and Hydrocodone.	Pain [MG30-MG3Z]	[68]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Triclabendazole.	Parasitic worm infestation [1F90]	[62]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Pimavanserin.	Parkinsonism [8A00]	[62]
Orphenadrine	DMW542E	Moderate	Additive antimotility effects by the combination of Loperamide and Orphenadrine.	Parkinsonism [8A00]	[63]
Ranitidine	DM0GUSX	Major	Decreased clearance of Loperamide due to the transporter inhibition by Ranitidine.	Peptic ulcer [DA61]	[62]
Methylscopolamine	DM5VWOB	Moderate	Additive antimotility effects by the combination of Loperamide and Methylscopolamine.	Peptic ulcer [DA61]	[63]
Macimorelin	DMQYJIR	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[62]
Lefamulin	DME6G97	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Lefamulin.	Pneumonia [CA40]	[62]
Lonafarnib	DMGM2Z6	Major	Decreased clearance of Loperamide due to the transporter inhibition by Lonafarnib.	Premature ageing appearance [LD2B]	[80]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Degarelix.	Prostate cancer [2C82]	[62]
ABIRATERONE	DM8V75C	Major	Decreased metabolism of Loperamide caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[62]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Loperamide caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[81]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Bicalutamide.	Prostate cancer [2C82]	[62]
Levomepromazine	DMIKFEL	Moderate	Additive antimotility effects by the combination of Loperamide and Levomepromazine.	Psychotic disorder [6A20-6A25]	[63]
Gatifloxacin	DMSL679	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[62]
Quetiapine	DM1N62C	Moderate	Additive antimotility effects by the combination of Loperamide and Quetiapine.	Schizophrenia [6A20]	[63]
Aripiprazole	DM3NUMH	Moderate	Additive antimotility effects by the combination of Loperamide and Aripiprazole.	Schizophrenia [6A20]	[63]
Iloperidone	DM6AUFY	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Iloperidone.	Schizophrenia [6A20]	[62]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Paliperidone.	Schizophrenia [6A20]	[62]
Perphenazine	DMA4MRX	Moderate	Additive antimotility effects by the combination of Loperamide and Perphenazine.	Schizophrenia [6A20]	[63]
Molindone	DMAH70G	Moderate	Additive antimotility effects by the combination of Loperamide and Molindone.	Schizophrenia [6A20]	[63]
Thiothixene	DMDINC4	Moderate	Additive antimotility effects by the combination of Loperamide and Thiothixene.	Schizophrenia [6A20]	[63]
Amisulpride	DMSJVAM	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Amisulpride.	Schizophrenia [6A20]	[62]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Asenapine.	Schizophrenia [6A20]	[62]
Vardenafil	DMTBGW8	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Vardenafil.	Sexual dysfunction [HA00-HA01]	[62]
LEE011	DMMX75K	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[62]
Vandetanib	DMRICNP	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[62]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[62]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[62]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Pitolisant.	Somnolence [MG42]	[62]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[62]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Loperamide caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[82]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Lenvatinib.	Thyroid cancer [2D10]	[62]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Loperamide and Papaverine.	Tonus and reflex abnormality [MB47]	[83]
Tacrolimus	DMZ7XNQ	Major	Decreased clearance of Loperamide due to the transporter inhibition by Tacrolimus.	Transplant rejection [NE84]	[65]
Pramlintide	DM0EZ9Q	Moderate	Altered absorption of Loperamide due to GI dynamics variation caused by Pramlintide.	Type-1/2 diabete [5A10-5A11]	[84]
Chlorpheniramine	DM5URA2	Moderate	Additive antimotility effects by the combination of Loperamide and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[63]
Methdilazine	DMAUHQX	Moderate	Additive antimotility effects by the combination of Loperamide and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[63]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[62]
Acrivastine	DMTIGA0	Moderate	Additive antimotility effects by the combination of Loperamide and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[63]
Procainamide	DMNMXR8	Moderate	Additive antimotility effects by the combination of Loperamide and Procainamide.	Ventricular tachyarrhythmia [BC71]	[63]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Propafenone.	Ventricular tachyarrhythmia [BC71]	[62]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Loperamide and Flecainide.	Ventricular tachyarrhythmia [BC71]	[62]
Amiodarone	DMUTEX3	Major	Decreased clearance of Loperamide due to the transporter inhibition by Amiodarone.	Ventricular tachyarrhythmia [BC71]	[65]
-----------


⏷ Show the Full List of 154 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Acesulfame	E00341	36573	Flavoring agent
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sucralose	E00370	71485	Flavoring agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Butylhydroxyanisole	E00308	24667	Antimicrobial preservative; Antioxidant
Calcium hydrogenphosphate	E00294	24441	Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Elemental iron	E00280	23925	Other agent
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Gelatin	E00630	Not Available	Other agent
Glycerin	E00026	753	Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Glyceryl monocaprylate	E00458	3033877	Emollient; Emulsifying agent; Surfactant
Hydrogenated polyoxyl 40 castor oil	E00662	Not Available	Emulsifying agent; Solubilizing agent; Surfactant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Tristearin	E00207	11146	Emollient; Viscosity-controlling agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 28 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Loperamide 2 mg tablet	2 mg	Chewable Tablet	Oral
Loperamide 2 mg tablet	2 mg	Oral Tablet	Oral
Loperamide 2 mg capsule	2 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	BDDCS applied to over 900 drugs
3	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
4	Loperamide: evidence of interaction with mu and delta opioid receptors. Life Sci. 1983;33 Suppl 1:315-8.
5	In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos. 2008 Feb;36(2):268-75.
6	Loperamide: a pharmacological review. Rev Gastroenterol Disord. 2007;7 Suppl 3:S11-8.
7	Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol. 2004 Oct;60(8):575-81.
8	Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats, dogs, and humans. Drug Metab Dispos. 1995 Mar;23(3):354-62.
9	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
10	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
11	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
12	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
13	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
14	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
15	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
16	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
17	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
18	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
19	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
20	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
21	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
22	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
23	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
24	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
25	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
26	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
27	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
28	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
29	Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
30	Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
31	Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
32	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
33	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
34	Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
35	Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
36	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
37	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
38	Drugs that may have potential CYP2B6 interactions.
39	Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
40	Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
41	PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
42	Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
43	Biochemical characterization of NfsA, the Escherichia coli major nitroreductase exhibiting a high amino acid sequence homology to Frp, a Vibrio harveyi flavin oxidoreductase. J Bacteriol. 1996 Aug;178(15):4508-14.
44	Absorption of (-)-nicotine-l-N-oxide in man and its reduction in the gastrointestinal tract. J Pharm Pharmacol. 1970 Sep;22(9):722-3.
45	Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954. Biochem Pharmacol. 2010 Mar 1;79(5):678-87.
46	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
47	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
48	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
49	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
50	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
51	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
52	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
53	Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16.
54	Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]. J Med Chem. 2004 Mar 11;47(6):1400-12.
55	Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
56	Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307.
57	Wax PM, Becker CE, Curry SC: Unexpected gas casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5.
58	Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior. Anesthesiology. 2011 December; 115(6): 1363-1381.
59	Delta-opioid receptor agonists inhibit neuromuscular transmission in human colon. Eur J Pharmacol. 1994 Sep 1;262(1-2):33-9.
60	Preclinical pharmacology of AZD2327: a highly selective agonist of the delta-opioid receptor. J Pharmacol Exp Ther. 2011 Jul;338(1):195-204.
61	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
62	Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
63	Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
64	Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
65	Adachi Y, Suzuki H, Sugiyama Y "Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in Situ and in Vivo." Pharm Res 20 (2003): 1163-9. [PMID: 12948013]
66	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
67	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
68	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
69	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
70	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
71	Cerner Multum, Inc. "Australian Product Information.".
72	Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
73	John L, Marra F, Ensom MH "Role of therapeutic drug monitoring for protease inhibitors." Ann Pharmacother 35 (2001): 745-54. [PMID: 11408994]
74	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
75	Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
76	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
77	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
78	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
79	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
80	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
81	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
82	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
83	Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
84	Product Information. Symlin (pramlintide). Amphastar Pharmaceuticals Inc, South El Monte, CA.